Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $20.00 at Wells Fargo & Company

Viridian Therapeutics (NASDAQ:VRDN) had its price objective decreased by Wells Fargo & Company from $29.00 to $20.00 in a report issued on Tuesday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Other analysts also recently issued reports about the stock. William Blair began coverage on shares of Viridian Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. HC Wainwright decreased their price objective on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday. Royal Bank Of Canada lowered their target price on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Wedbush cut their target price on shares of Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Wall Street Zen lowered shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Stock Up 5.6%

Shares of Viridian Therapeutics stock opened at $19.56 on Tuesday. The business has a fifty day simple moving average of $29.16 and a 200 day simple moving average of $27.89. The stock has a market cap of $2.00 billion, a PE ratio of -5.95 and a beta of 1.00. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Research analysts predict that Viridian Therapeutics will post -4.03 EPS for the current year.

Institutional Trading of Viridian Therapeutics

A number of large investors have recently bought and sold shares of the business. MetLife Investment Management LLC raised its holdings in Viridian Therapeutics by 0.8% during the 4th quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock worth $1,369,000 after buying an additional 356 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Viridian Therapeutics by 0.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after buying an additional 380 shares during the period. US Bancorp DE boosted its holdings in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after acquiring an additional 876 shares in the last quarter. Finally, Virtus Investment Advisers LLC raised its holdings in shares of Viridian Therapeutics by 13.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock worth $256,000 after acquiring an additional 971 shares during the period.

Key Stories Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.